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Transcatheter aortic valve replacement (TAVR) has trans-
formed the care of patients with aortic stenosis. The dissem-
ination of this technology after its approval in the United
States in the wake of a pivotal randomized trial1,2 has thus
far proceeded in a thoughtful and circumspect manner,
guided by a coalition of stakeholders dedicated to the
delivery of high-quality, patient-centered care. It is antici-
pated that a number of transcatheter therapies for mitral
regurgitation (MR) will also become available for clinical
use in selected patients. As an example, the MitraClip de-
vice (Abbott Vascular, Santa Clara, Calif) was approved
October 24, 2013, for the reduction of significant (3þ),
symptomatic, degenerative MR in highly anatomically
selected patients considered by an experienced heart team
to be at prohibitive risk for mitral valve surgery. Other trans-
catheter approaches in development include mitral
annulus–based therapies, transapical neochordal implants,
valve-in-valve and valve-in-annuloplasty ring therapies,
and valve replacement therapies. A process similar to that
adopted for TAVR is proposed to ensure that such innova-
tive treatments are introduced into medical practice in the
United States with appropriate safeguards.3 The American
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Clinical Guidelines O’Gara et alfor Thoracic Surgery (AATS), The Society of Thoracic Sur-
geons (STS), and the Society of Cardiovascular Angiog-
raphy and Interventions (SCAI) Foundation have
collaborated to write this overview to set the stage for an
ensuing series of documents, to be joined by other profes-
sional societies, and to address the issues critical to the
appropriate integration of transcatheter MR therapies into
the care of selected patients with this disorder. In accor-
dance with the ACC’s policy on relationships with industry
and other entities (RWI), relevant author disclosures are
included in Appendix 1 of this document. In the spirit of
full disclosure, authors’ comprehensive RWI information,
which includes RWI not relevant to this document, is
available online as a data supplement to this document
(http://jaccjacc.cardiosource.com/acc_documents/2013_
TTMR_Comprehensive_Author_Disclosure_Table.pdf).
RWI restrictions do not apply to participation in the external
peer review process for clinical documents, in order to
ensure that a variety of constituencies/perspectives inform
the final paper. However, for purposes of full disclosure, all
relevant RWI for reviewers, as well as their individual affilia-
tions, are published in Appendix 2. Final review and approval
of thedocumentwasprovided by the respective boardsof the 4
professional societies. These organizations are committed to
providing guidance on key issues having an impact on clinical
care and believe this documentwill help frame subsequent dis-
cussions regarding such technology as it continues to evolve.1. INTRODUCTION
Catheter-based therapies for valvular heart disease,
including balloon valvuloplasty, have been in clinical use
for over 3 decades. More recently, transcatheter valve
replacement technologies have dramatically altered the
approach to children and adults with congenital or post-
surgical pulmonic valve disease and to adults with degener-
ative aortic stenosis. Using the lessons learned from the
release of these transformational technologies, this docu-
ment seeks to highlight the critical issues surrounding adult
transcatheter MR therapies to properly align the interests of
all relevant stakeholders, including primary care physicians;
patients and their families; proceduralists (interventional
cardiologists, cardiac surgeons); heart valve, heart failure,
and imaging experts; general and geriatric cardiologists;
other heart team members; and regulators, payers, profes-
sional societies, and industry. In order to promote the expan-
sion of this technology to allow for best patient outcomes,
new guidelines and requirements for training, operator cre-
dentialing, and institutional policies will be developed.1.1. Key Questions
1. How will this technology be regulated and by what
authority?838 The Journal of Thoracic and Cardiovascular Surg2. Will the technology be available in all centers to all inter-
ested parties, or will it be restricted to specialized cen-
ters? If the latter, how will these centers be specified?
What constitutes a heart valve center of excellence?
Are the characteristics of a valve reference center the
same for aortic and mitral disease?
3. What training will be required for interventional cardiol-
ogists and surgeons, and how will it be accomplished?
Will the training be the same for cardiologists and sur-
geons? What criteria will be utilized to grant procedural
privileges?
4. What clinical, procedural, administrative, and follow-
up data will be collected and by what mechanism to
ensure rigorous assessment of outcomes across
centers and provide a framework for comparative
effectiveness research and cost-effectiveness assess-
ment? How will patient cohorts that are most and
least likely to benefit from this technology be identi-
fied?
5. What mechanisms will exist to allow for the careful
extension of this technology to the treatment of other
groups of patients not included or studied in the initial,
randomized clinical trials?
6. How will this technology be reimbursed? Will there be a
national coverage determination?
Answers to these questions are complex and influenced in
large measure by the number of interested stakeholders.
Transcatheter treatment of MR is technically challenging
and thus far of limited scope. Maintaining the best interests
of patients constitutes the driving force behind any initiative
of this type.2. MITRALVALVE SURGERY
MR can result from abnormalities in the structure and/
or function of 1 or more of the 4 components of the mitral
apparatus (leaflets, annulus, chordae tendineae, and papil-
lary muscles/left ventricular [LV] myocardium). Primary
MR refers to abnormalities of the leaflets and is most
commonly due to myxomatous degeneration, especially
in developed countries. With secondary or functional
MR, the leaflets are usually normal, and the regurgitation
occurs as a consequence of adverse LV remodeling, with
papillary muscle displacement, leaflet tethering, and
annular dilatation. The prevalence of moderate to severe
mitral valve disease (more often regurgitant rather than
stenotic) increases as a function of age and exceeds that
of aortic valve disease on both a community and popula-
tion level when assessed by echocardiography.4 Prognosis
with MR differs as a function of both etiology and LV
function; treatment protocols, including medical interven-
tions and cardiac resynchronization therapy when
indicated, must be tailored to the underlying disease
substrate.ery c March 2014
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of MR have evolved considerably over the past several de-
cades as both operative techniques and patient outcomes
have improved.5,6 These trends are especially true for
patients with severe, degenerative MR of a myxomatous
nature for whom valve repair has become the preferred
strategy whenever feasible. Isolated valve repair for this
indication can now be accomplished through a variety of
minimally invasive approaches, including with the use of
robotic techniques in highly specialized surgical centers.
Patients are interested in pursuing less invasive
approaches in the hopes of reducing the burden of
perioperative complications and discomfort, without
compromising their chances for a successful and durable
outcome. Expert mitral valve surgeons may employ
several techniques to accomplish this task, including
leaflet resection, neochordal construction, prosthetic ring
or band insertion, and edge-to-edge leaflet approximation.
Emerging transcatheter technologies have attempted to
replicate 1 or more of these surgical principles, thus far
with varying success in clinical and experimental settings.
Perioperative mortality rates for selected, low-surgical-risk
patients with severe degenerative MR are now<1% in
major referral centers where a successful repair can be
accomplished in over 95% of patients with isolated poste-
rior mitral leaflet pathology. Nevertheless, there remains
concern that patients with severe, degenerative MR are
not referred for surgical intervention in a timely fashion,
even in referral centers of excellence.7 On the other end
of the spectrum, symptomatic patients with functional
MR that is due either to adverse LV remodeling after
myocardial infarction or to a nonischemic cardiomyo-
pathic process may benefit from surgical treatment to
reduce or eliminate the excess LV volume load. A
down-sized annuloplasty repair or chordal-sparing valve
replacement is undertaken as dictated by the anatomic
and hemodynamic features encountered in an individual
patient. Many such patients are considered intermediate-
to-high risk for perioperative mortality or major complica-
tions. A less invasive approach, in combination with
percutaneous coronary intervention for concomitant treat-
ment of important coronary artery disease, may be of
value in this setting. The use of transcatheter mitral valve
repair in patients with functional MR appears to be both
feasible and beneficial for selected patients.8 As these
technologies become available for patients with either
degenerative or functional MR, it will be important for
experienced referral centers and cohesive heart teams to
guide their deployment into clinical practice. As well,
the short- and long-term efficacy, safety, comparative
effectiveness and cost of these technologies must be eval-
uated through a dynamic registry supported by relevant
stakeholders.The Journal of Thoracic and Ca3. CRITICAL COMPONENTS FOR SUCCESSFUL
TRANSCATHETER MR THERAPIES
3.1. Heart Team
The heart team approach, as utilized in the landmark
SYNTAX (TAXUS Drug-Eluting Stent versus Coronary
Artery Bypass Surgery for the Treatment of Narrowed Ar-
teries; NCT00114972)9 and PARTNER (Placement of
Aortic Transcatheter Valve; NCT00530894)1,2 trials, and
embedded in the management of patients with advanced
heart failure, is now an established paradigm for the care
of patients with complex coronary or aortic valve disease.
This approach was also followed in EVEREST
(Endovascular Valve Edge-to-Edge Repair Study), which
evaluated the efficacy and safety of the MitraClip.10-12
The keymembers of the heart team for transcatheter ther-
apies for MR include primary (general) cardiologists,
interventional cardiologists, cardiac surgeons, imaging spe-
cialists, valve and heart failure specialists, electrophysiolo-
gists, cardiac anesthesiologists, catheterization laboratory
technologists, perfusionists, nurses, nurse practitioners,
physician assistants, care coordinators, research coordina-
tors, administrators, nutritionists, physical therapists, exer-
cise physiologists, and social workers. At times, it will be
appropriate to include a geriatric cardiologist or geriatri-
cian, particularly when assessing frailty/comorbidities of
the older adult; additional consultants may be required
(nephrology, neurology, or oncology). A heart team leader
is responsible for the coordination and integration of these
several contributors.3.1.1. Role of the Primary Cardiologist
The initial diagnosis and management of the patients
with MR resides with the primary cardiologist whose
clinical decision making is informed by echocardio-
graphic imaging, other imaging, and exercise data as
needed. He or she will determine the timing of referral
for intervention and then work with the interventional
cardiologist and cardiac surgeon to determine the best
course of action based on an individualized risk/benefit
analysis and an understanding of patient values and pref-
erences. The primary cardiologist is often in the best po-
sition to communicate with the family throughout the
care process and will provide longitudinal follow-up after
the procedure, in coordination with the interventionalist
and surgeon.
3.1.2. Role of the Imaging Specialist(s)
Accurate assessment of mitral valve anatomy and
function requires a portfolio of imaging capabilities,
including 2- and 3-dimensional transthoracic and transeso-
phageal echocardiography and cardiac magnetic resonance
imaging. Quantitative assessment of the severity of mitralrdiovascular Surgery c Volume 147, Number 3 839
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before the procedure and at follow-up. Additional insights
are to be gained through coronary angiography (either inva-
sive or noninvasive) and delineation of the anatomic rela-
tionship between the coronary sinus and the mitral
annulus. Standardized datasets should be collected and
the American Society of Echocardiography definitions of
severe MR11 should be incorporated in registry reporting.
The need for other arterial or venous imaging will be driven
by the specificmitral valve technology and its method of de-
livery. It is essential for the imaging specialist to be
skilled in providing live imaging capabilities because they
are often required to assist in the procedure.3.1.3. Role of the Heart Valve and Heart Failure Specialist
Heart valve and heart failure specialists are important
contributors to the heart team. The perspective of a heart
failure specialist is particularly appropriate for the assess-
ment and management of patients with MR and LV systolic
dysfunction of any etiology.
3.1.4. Role of the Interventional Cardiologist
The interventional cardiologist will be skilled in all
aspects of transcatheter structural and coronary heart dis-
ease procedures. He or she will work collaboratively with
the other members of the heart team in the evaluation and
procedural management of the patient, as well as with early
post-procedural follow-up. Knowledge of mitral valve dis-
ease, imaging, hemodynamics, procedure specifics, adjunct
medications, and complications is mandatory. Specific
competencies will be addressed in a forthcoming multiso-
cietal document.
3.1.5. Role of the Cardiac Surgeon
The cardiac surgeon will see patients in collaboration
with the primary and interventional cardiologist and be
competent in catheter-based and surgical approaches to
MR, including repair and replacement options. Specific
competencies will be addressed in a forthcoming multiso-
cietal document. It is recognized that some surgeons have
experience with and expertise in catheter-based techniques
gained through TAVR procedures. The cardiac surgeon and
interventional cardiologist will collaborate during the per-
formance of transcatheter mitral procedures and will desig-
nate the primary and secondary operator as appropriate for
the specific findings and challenges encountered in any
individual patient.
3.2. Specialized Facilities
3.2.1. Regional Heart Centers
Many cardiac catheterization and cardiac surgical pro-
grams have a low volume of structural heart disease cases.
In low-volumecenters, for example,mitral valve replacement840 The Journal of Thoracic and Cardiovascular Surgmay be performedmore frequently than appropriate forman-
agement of patients with degenerativeMR forwhom repair is
strongly recommended. In addition, patient outcomes
vary inversely as a function of operator and institutional
volume.12,13 The National Institutes for Health and Clinical
Excellence in the United Kingdom have recommended
volume criteria for mitral valve repair.14 The challenges of
evaluating and managing patients with MR and significant
comorbidities, such as heart failure, requiremultidisciplinary
teamcare in a high-volume referral centerwith the infrastruc-
ture necessary to ensure best outcomes. The example estab-
lished by the dissemination of TAVR should pertain to the
release of therapies forMR. Accordingly, a detailed list of fa-
cilities and personnel experience, pre- and post-procedural
care protocols, and complication management strategies
must be developed and maintained. All data must be stan-
dardized and sent to a central registry for analysis and report-
ing. The level of commitment needed at the institutional level
to establish and maintain the program cannot be overstated.
3.2.2. Procedure Setting
A cardiac catheterization laboratory with adequate space
(800 sq ft) to accommodate the operators, imagers, car-
diac anesthesiologists, support staff, and their necessary
equipment (including transesophageal echocardiography
equipment, anesthesia machines, and intra-aortic balloon
pumps) is mandatory. There must be high-quality, single-
plane fluoroscopy and cineangiography. Other imaging
modalities, such as computed tomography and magnetic
resonance imaging with real-time 3-dimensional recon-
struction, are expected to play an increasing role during
the procedure. A hybrid operating suite is not strictly neces-
sary for mitral procedures at this stage of development, but
laminar air flow to provide operating room–level sterility is
mandatory. Should a transcatheter mitral valve replacement
option evolve, however, a hybrid suite with the capability
for cardiopulmonary bypass would be needed. The equip-
ment necessary to perform the procedure, including wires,
sheaths, balloons, and devices of multiple sizes must be
available. Support staff may include individuals with a pre-
dominant background and skill set in either interventional
or surgical procedures, as dictated by patient- and
procedural-specific needs. Procedural teams function
best with both disciplines represented and working
collaboratively.
It is anticipated that patients will be cared for in special-
ized cardiac or cardiac surgical intensive care units after the
procedure, then transitioned to telemetry care as their
hemodynamics, rhythm, respiratory status, and vascular
access issues allow. It will be important for institutions to
designate a single intensive care area for post-procedural
care to optimize expertise, team training, and the develop-
ment of care protocols. Expertise may require integration
of cardiac and surgical nursing competencies.ery c March 2014
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4.1. Clinical Trials in the United States
Approaches under investigation for transcatheter mitral
valve repair or replacement include the edge-to-edge clip,
off-pump adjustable neochordal implantation, indirect an-
nuloplasty (generally via coronary sinus remodeling),
cinching devices to induce annular reduction, external
compression, direct annuloplasty (transcatheter surgical
rings or sutures), energy-mediated annuloplasty (collagen
shrinking), and transcatheter mitral valve replacement. Of
the above technologies, the edge-to-edge MitraClip has un-
dergone the most extensive human investigation thus far.15
This device is fashioned after a direct surgical method that
relies on suture approximation of the leaflets to create a dou-
ble orifice valve.16
The initial U.S. experience with transcatheter mitral
valve repair for MR in 27 patients using the MitraClip
was reported in the EVEREST phase I trial in 2005,17
with a subsequent expanded analysis in 2009 of 107 patients
with at least 1-year follow-up.10 This initial experience was
favorable in terms of acute procedural success, safety, and
functional outcome, although 30% of patients required
mitral valve surgery for treatment of 3 or 4þ MR within
3.2 years of device implantation.
The pivotal EVEREST II trial (NCT00209274) random-
ized 279 patients with 3 or 4þ chronic MR secondary to
malcoaptation of the middle scallop of the anterior and pos-
terior leaflets in a 2:1 ratio to transcatheter MitraClip repair
versus open surgical repair.18 The primary efficacy endpoint
at 12 months (composite of freedom from death, surgery for
mitral valve dysfunction, and 3 or 4þ MR) was reached in
57% of transcatheter MitraClip repair patients versus 73%
of surgical patients (P¼ .007). Mortality rates were similar
between groups and the efficacy outcome difference was
driven by a 20% incidence rate of surgery for mitral valve
dysfunction in theMitraClip arm (vs 2% in the surgery arm,
P<.001). Although the rate of 3 or 4þ MR at 12 months
was nearly identical for the groups (21% transcatheter
repair vs 20% surgery), in this intention-to-treat analysis,
patients assigned to surgery, but who did not undergo sur-
gery, were considered treatment failures. In a per-protocol
analysis, freedom from death, mitral valve surgery for
persistent MR, and the occurrence of 3 to 4þ MR at 12
months was 72% for the transcatheter arm compared with
88% for surgery (P ¼ .02). The incidence rates for 3 to
4þ MR at 1 year in this per-protocol analysis were 17%
in the transcatheter therapy arm versus 4% in the surgery
arm (P ¼ .01). The primary safety outcome, a composite
of major adverse events at 30 days, favored the transcatheter
group (15% transcatheter repair arm vs 48% surgery arm;
P<.001). The higher rate of major adverse events in the sur-
gery arm at 30 days was driven largely by an excess hazard
of transfusion of 2 or more units of blood (13%The Journal of Thoracic and Catranscatheter repair arm vs 45% surgery arm; P< .01).
With open surgery, the incidence of major morbidity, as
defined by the STS, was 9% versus 2% in the transcatheter
arm (P ¼ .02). At 4 years, overall mortality was similar be-
tween groups (17% transcatheter arm vs 18% surgery; P¼
.91) with mitral valve surgery or reoperation more often
necessary following transcatheter repair (25% transcatheter
arm vs 5% surgery arm, P<.001).19 Following transcath-
eter repair at 4 years, MR grade was 0 to 1þ in 42% of
patients, 2þ in 37%, and 3 to 4þ in 21%. Following surgi-
cal repair at 4 years, MR grade was 0 to 1þ in 82%, 2þ in
9%, and 3 to 4þ in 9% (P<.001).
Seventy-eight patients with 3 or 4þ symptomatic MR for
whom the predicted perioperative mortality rate was12%
were enrolled in the EVEREST II High Risk Study
(HRS).20 Fifty-six percent of patients had functional MR,
and 44% of patients had degenerativeMR. A referent group
of patients who were screened concurrently, but not
enrolled, allowed for survival comparison with a group
managed conservatively. In the treated group, the MitraClip
reduced the severity of MR in a majority of patients and was
associated with improved symptoms, LV reverse remodel-
ing, recurrent heart failure hospitalizations, quality of life,
and survival at 12 months.20 Implantation of the MitraClip
was successful in 95% of 127 prohibitive-surgical-risk pa-
tients with degenerative MR treated between 2003 and
2012.21 One-year survival was 74% and was associated
with similar improvements in functional status, quality of
life, indices of LV remodeling, and recurrent hospitaliza-
tions for heart failure in this anatomic cohort.
Salutary effects included reduced MR grade, LV reverse
remodeling, fewer rehospitalizations for heart failure, and
improved quality of life. The COAPT (Clinical Outcomes
Assessment of the MitraClip Percutaneous Therapy for
High Surgical Risk Patients; NCT01626079) and
RESHAPE-HF (Randomized Study of the MitraClip De-
vice in Heart Failure Patients With Clinically Significant
Functional Mitral Regurgitation; NCT01772108) trials
have been designed to evaluate the MitraClip therapy in
very high surgical risk patients with functional MR, reduced
LVejection fraction, and New York Heart Association func-
tional class III or IV heart failure.
4.2. European Registry and Observational Studies
The MitraClip system received CE Mark approval in
March 2008 and commercialization began in September
2008. The ACCESS-EU (ACCESS-Europe A Two Phase
Observational Study of the MitraClip System in Europe)
phase I study began enrolling patients in Europe in April
2009. Enrollment in ACCESS-EU phase I was completed
on April 13, 2011, and 12-month clinical data collected as
of June 15, 2012, were reported in September 2013.22 The
implant success rate was 99.6% for 567 patients (Euro-
SCORE [European System for Cardiac Operative Riskrdiovascular Surgery c Volume 147, Number 3 841
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day and 1-year mortality rates were 3.4% and 19%, respec-
tively. By 1 year, open mitral valve surgery was necessary in
6.3% of patients, 3.4% of patients required a secondMitra-
Clip procedure to treat residual MR, and the incidence of 3
to 4þ MR was 21%. Among the 1-year survivors, 71%
were in New York Heart Association functional class I or
II with improvements in 6-min walk test and quality of
life scores. With functional valve disease, MR grade at 1
year was 3 to 4þ in 21%, 2þ in 47%, and 0 to 1þ in
32% of patients. With degenerative valve disease, MR
grade at 1 year was 3 to 4þ in 25%, 2þ in 42%, and 0 to
1þ in 33% of patients. In this post-approval European
experience, MitraClip therapy was most frequently applied
to high-risk, elderly patients, mainly with functional MR.
Several other European observational studies in patients
with both degenerative and functional MR, including
high-surgical-risk patients, have been reported with direc-
tionally similar results.23-28 Investigators have cautioned
that pre-assessment, treatment, and post-procedural care
by an interdisciplinary team are essential to maximize clin-
ical success, especially in high-surgical-risk patients. The
2012 European Society of Cardiology Guidelines on the
Management of Valvular Heart Disease state that MitraClip
may be considered for patients with life expectancy>1 year
and symptomatic severe, secondary (functional) MR
despite optimal medical therapy (including cardiac re-
synchronization therapy when indicated) who are deemed
high risk or inoperable by a formal heart team (Class IIb,
Level of Evidence: C).6 Surgical repair after failed Mitra-
Clip deployment is feasible, although more extensive valve
scarring after clip implantation may necessitate valve
replacement.29 Thirty-seven of 178 MitraClip patients in
EVEREST II underwent open mitral valve surgery within
12 months of implant. Valve repair was possible in 20 pa-
tients, and valve replacement was required in 17 patients.
Removal of the MitraClip was more difficult after 30 days
because of fibrosis and scarring of the leaflets. Anterior
leaflet pathology was a predictor of the need for valve
replacement.30
4.3. Other Transcatheter Mitral Valve Technologies
Transcatheter mitral annuloplasty via the coronary sinus
has been assessed in the CARILLON AMADEUS (Mitral
Annuloplasty Device European Union)31 and TITAN
(Transcatheter Implantation of Carillon Mitral Annulplasty
Device)32 trials using the CARILLON Mitral Contour Sys-
tem (Cardiac Dimensions, Kirkland, Washington), and in
studies using an alternative device (PTOLEMY [Safety
and Efficacy of the Percutaneous TransvenousMitral Annu-
loplasty (PTMA) Device]; NCT00568230).33 Recruitment
in a subsequent evaluation of the PTMA device (PTOLE-
MY2Canada [Safety and Efficacy Study of the PTMA
Device to Reduce Mitral Valve Regurgitation in Patients842 The Journal of Thoracic and Cardiovascular SurgWith Heart Failure]; NCT00815386)34 was suspended
once the device manufacturer ceased operations in 2011.
Technical and anatomic challenges have thus far impeded
application of coronary sinus annuloplasty devices although
a potential adjunct role for their use in selected patients may
emerge. Transapical beating heart mitral valve repair with
deployment of neochordae has been reported.35 Human
experience with other transcatheter devices, such as a septal
sinus shortening system, has been extremely limited to
date.36
5. OPERATOR TRAINING
It is incumbent on professional societies to set minimal
performance standards for these procedures rather than to
defer to commercial sponsors. The societies should develop
the curriculum, establish the metrics for evaluation, and
certify completion of a training module. Challenges to
this paradigm include access to a required minimum of
cases, the appropriate balance of simulation and/or large an-
imal laboratory experience, the limited number of centers at
which these procedures have been performed to date, the
limited number of senior mentors, and the disadvantages
faced by operators and surgeons who have graduated from
training programs and are now in practice. Our societies
have outlined the specifics of a training curriculum in inter-
ventional fellowships for structural and adult congenital
heart disease.37 Unanswered questions concern the duration
of training, funding, team-based training needs, and the
expectations for interventionalists and surgeons. The estab-
lishment of such training criteria, procedural volumes, and
performance and evaluation metrics are beyond the scope of
the document and will be addressed in the forthcoming
SCAI/AATS/ACC/STS Multisocietal Consensus State-
ment: Operator and Institutional Requirements for Trans-
catheter Valve Repair and Replacement: Part 3: Mitral
Valve.38
6. PROTOCOLS FOR CARE
Specific protocols for pre-, intra-, and post-procedural
patient assessment and care should be in place with clear
delineation of the roles of the individual heart team mem-
bers and establishment of a collaborative process for shared
decision making with the patient. Protocols should involve
assessment of mitral valve anatomy and function, cardiac
chamber sizes, biventricular function, pulmonary artery
pressures, and any concomitant aortic or tricuspid valve pa-
thology. Knowledge of the coronary anatomy will be
required. A complete assessment of medical comorbidities
is a key component of this process. The need for other pro-
cedures (such as coronary revascularization) that may be
indicated to achieve an optimal result should be identified.
All patients referred for consideration of transcatheter ther-
apy for MR should proceed down the same evaluation and
treatment pathway so as to promote consistency, reduceery c March 2014
O’Gara et al Clinical Guidelinesvariability, and allow for more uniform reporting of results.
The process should help prevent inappropriate use of the
technology, as well as post hoc misinterpretation of the
data needed for optimal device utilization. Provision of
longer-term follow-up care must be specified and protocols
for surveillance imaging established.
7. ASSESSMENT OF OUTCOMES
Clinical, procedural, device, and administrative data
collection, analysis, and reporting are vital aspects of the
processwhereby the utility and safety of anynew technology
can be established. The value of robust patient registries has
been demonstrated most convincingly by the STS National
Database and the ACCNational Cardiovascular Data Regis-
try (NCDR). In the ASCERT (ACCF/STS Collaboration on
the Effectiveness of Revascularization Strategies) study,
these 2 databases were conjoined and then linked to the So-
cial SecurityDeathMaster File and theCenters forMedicare
& Medicaid Services (CMS) Medicare Provider and Anal-
ysis Review repositories to inform outcomes analysis and
comparative effectiveness research on real-world patients
undergoing coronary revascularization.39 A novel, national
clinical registry program for new transcatheter valve therapy
(TVT) devices was created in December 2011 following
Food and Drug Administration (FDA) approval of the Sa-
pien Transcatheter Aortic Valve.40 The TVT registry
(NCT01737528), a joint initiative of the STS and ACC,
was developed in close collaboration with the FDA, CMS,
and the Duke Clinical Research Institute.41 Its purpose is
to provide an objective, comprehensive, and scientifically
based resource to improve the quality of patient care,
monitor the safety and effectiveness of novel transcatheter
valve technologies, serve as a platform for TVT research,
and enhance communication among multiple stakeholders.
It is linked to other national and international registries to
facilitate its mission. Importantly, the TVT registry fulfills
the CMS National Coverage Determination (NCD) (May
2012) requirement for national registry participation for all
TAVR centers. The registry enables device and procedure
surveillance, quality improvement, and the performance of
device labeling studies to speed access to new devices and
support expansion of labeling with evidence development.
The first TVT registry–embedded post-approval study was
developed in partnership with the FDA and Edwards Life-
sciences, the industry sponsor of the first FDA-approved
transcatheter aortic valve. Several more are now under dis-
cussion and in early development. The first embedded inves-
tigational new device study undertaken through the registry
and sponsored by STS and ACC, with the approval of FDA
and CMS, led in a short time to expanded indications for
TAVR.42 The addition of transcatheter MR therapies and
other heart valve lesions is a logical and necessary extension
of the TVT registry. The process to incorporate mitral tech-
nologies has already begun, with careful delineation of theThe Journal of Thoracic and Cacritical data elements thatmust be captured in a standardized
and well-defined manner with seamless linkage to other da-
tabases and harmonization with pivotal clinical trials to
inform regulatory approval, promote best practices, and
ensure high-quality patient-centered care. It is anticipated
that participating centers will collect information regarding
patient demographics, comorbidities, functional status,
patient-reported quality of life, hemodynamics, procedural
details, and post-procedure 30-day and 1-year outcomes.8. SUMMARYAND RECOMMENDATIONS
Transcatheter therapies hold promise for themanagement
of carefully selected patients with severe MR using less
invasive means whereby the experience of care may be
improved. Although registry experience in the United States
and Europe has been encouraging, only a single randomized
trial using a specific device in patients with MR has been re-
ported with recent FDA approval for use of this device in
eligible U.S. patients with degenerative MR. Further
research involving a wider spectrum of patients and devices
is strongly encouraged. It is recognized that the intricate
structure and complex function of the mitral apparatus
pose challenging technical hurdles. It is imperative that pro-
fessional societies, industry, payers, and regulatory agencies
work collaboratively to promote needed research and ensure
that the technology is disseminated rationally and respon-
sibly in the best interests of patients. The following recom-
mendations for a path forward closely mirror those
enunciated in a previous ACCF/STS Societal Overview.3
The leadership of our organizations proposes:
1. Continued development of regional heart valve referral
centers of excellence. Criteria for the performance of
transcatheter therapy for MR in such centers should be
established and refined. Availability of new devices
and reimbursement for their application should be
limited to those centers that meet national criteria.
2. A heart valve referral center of excellence is defined in
part by the competence and experience of the individual
members of a dedicated, multidisciplinary heart team,
each of whom has a clearly defined role and works
collaboratively in the best interest of patients. Input is
required from general cardiologists, heart valve and
heart failure experts, advanced imagers, interventional-
ists, cardiac surgeons, and allied members of the heart
team (eg, anesthesia, geriatrics, neurology, nephrology,
nursing, care coordination, pharmacy, physical therapy,
and social work). All aspects of patient evaluation and
care must be addressed, including late follow-up. Lack
of dedicated care pathways should disqualify a center
from participation.
3. All centers are required to participate in an ongoing TVT
registry to benchmark quality and enable outcomes and
cost analysis, aswell as comparative effectiveness research.rdiovascular Surgery c Volume 147, Number 3 843
Clinical Guidelines O’Gara et alData quality, as well as productivity in publication of
research projects from the registry, should be monitored.
4. Operator training and credentialing criteria for mitral
valve procedures must be established and are the subject
of a joint professional competency document in develop-
ment.
5. Guidelines for transcatheter mitral valve interventions
should be substantiated and developed. Performance
measures and appropriate use criteria would follow.
Presently, the MitraClip is approved only for prohibitive
surgical risk patients with degenerative MR who meet
anatomic eligibility criteria. The COAPT trial
(NCT01626079) will address the role of the MitraClip
device in high surgical risk patients with functional MR.
The ACC, AATS, SCAI, and STS are committed to the
principle of working collaboratively together as profes-
sional societies and in partnership with the FDA, CMS,
and industry partners to bring promising, innovative mitral
valve technologies into clinical practice as validated by the
evidence and in the best interests of patients.
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